Best of IBD Summit: Challenging Clinical Scenarios, Sequencing Therapies, and Emerging Therapies
This activity is supported by educational grants from AbbVie Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by educational grants from AbbVie Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Activity Description
Inflammatory Bowel Disease (IBD), including conditions like Crohn's disease (CD) and ulcerative colitis (UC), varies widely in severity among patients. A comprehensive approach to IBD management involves evaluating disease severity, optimizing therapy through monitoring, considering patient-reported outcomes, and tailoring treatments based on individual characteristics and preferences. This approach, supported by shared decision-making and collaboration among healthcare professionals, contributes to better outcomes for patients with IBD.
In this activity, experts in the field review topics of IBD with dysplasia, perianal fistulizing CD, sequencing therapies in patients with CD, and lastly a look at new and emerging treatments with unique mechanisms of action in IBD.
Target Audience
The intended audience for this activity is gastroenterology fellows, gastroenterologists, internists, nurse practitioners, and physician associates involved in the management of patients with IBD.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Describe the significance of optimal positioning of current IBD therapies and the use of patient-reported outcomes to inform treatment decisions.
- Evaluate strategies to individualize IBD management based on patient characteristics/preferences including shared decision-making and interprofessional strategies for improved outcomes.
- Summarize the clinical evidence for current and emerging therapies for IBD.
- Assess the use of biologics and small molecule therapies for the treatment of patients with IBD.
- List the reasons for loss of response to biologics and strategies for the effective sequencing of IBD therapies.
Activity Co-Chairs
David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine and Professor of Pathology
Chief, Section of Gastroenterology, Hepatology and Nutrition
University of Chicago Medicine
Chicago, IL
Corey A. Siegel, MD, MS
Constantine and Joyce Hampers Professor of Medicine
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, Inflammatory Bowel Disease Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH
Faculty
Brian L. Bressler, MD, MS, FRCPC
Founder, The IBD Centre of BC
Director, Advanced IBD Training Program Clinical Associate Professor of Medicine
Division of Gastroenterology
University of British Columbia
Vancouver, Canada
Parambir S. Dulai, MD
Associate Professor of Medicine
Director of GI Clinical Trials and Precision Medicine
Division of Gastroenterology and Hepatology
Feinberg School of Medicine Northwestern University
Chicago, IL
Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, OH
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participants who opt in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
American Academy of Physician Associates (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME. PAs may receive a maximum of 1.75 credit hours for completing this program.
This enduring material is approved for 1 year from the date of original release, December 15, 2023, to December 14, 2024.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Co-Chairs and Faculty report the following relevant financial relationship(s)
Brian L. Bressler, MD, MS, FRCPC
Consultant: AbbVie, Alimentiv, AMT, Bausch Health, BIOJAMP, Bristol Myers Squibb, Celgene, Celltrion, Eupraxia, Ferring, Fresenius Kabi, Gilead, Iterative Health, Janssen, Merck, Mylan, Organon, Pendopharm, Pfizer, Sandoz, Takeda, Viatris
*Individual Stocks and Stock Options (privately held): Qu Biologics
Parambir S. Dulai, MD
Royalties or Patent Beneficiary: University of California San Diego
Consultant: AbbVie, Adiso Therapeutics, Bristol Meyers Squibb, Geneoscopy, GSK, Janssen, Lilly, Pfizer, Roivant Sciences, Takeda
Speaker Contracted by Ineligible Company: AbbVie, Bristol Meyers Squibb, Janssen
Miguel Regueiro, MD, AGAF, FACG, FACP
Royalties or Patent Beneficiary: Crohn's & Colitis Foundation, Wolters Kluwer Health
Advisory Board/Consultant: AbbVie, Alfasigma S.p.A., Allergan, Amgen, Bristol Myers Squibb, Celgene, Genentech, Gilead, Janssen, Lilly, Miraca, Pfizer, Prometheus, Salix, Seres, Takeda, TARGET PharmaSolutions, UCB
Unrestricted Educational Grants: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Gilead, Janssen, Lilly, Pfizer, Takeda, UCB
David T. Rubin, MD
Consultant: AbbVie, Alimentiv, AltruBio, Amgen, Avalo Therapeutics, Bristol Myers Squibb, Buhlmann Diagnostics Corp, ClostraBio, Connect Biopharma, Datos Health, EcoR1, Evinature, Ferring Pharmaceuticals, Image Analysis Group, Janssen, Lilly, Menten AI, NeuroLogica, Odyssey Thera, Pfizer, Prometheus, Reistone, Sangamo, Takeda, Target RWE, TISSIUM, Trellus Health
Independent Research Contractor: Takeda
*Individual Stocks and Stock Options (privately held): AltruBio, Datos Health
Board of Trustees: Crohn's & Colitis Foundation
Corey A. Siegel, MD, MS
Consultant: AbbVie, Bristol Myers Squibb, Celltrion, Fresenius, Janssen, Lilly, Napo Pharmaceuticals, Pfizer, ProciseDx, Prometheus, Roivant, Takeda, Trellus Health
Independent Research Contractor: AbbVie, Janssen, Pfizer, Takeda
*Does not to speak to business lines or products of the company(ies)
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
ADA Compliance
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Lecture is available upon request. Requests should include the Activity title and emailed to CME@VindicoCME.com. Requests will be honored within 3 to 5 business days.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by getting in touch with our designated copyright agent (as outlined below). To do so, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (e.g., URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you either are the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com